DNA Group (TR) (XTAE:DNA) EBIT : ₪-1.98 Mil (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is DNA Group (TR) EBIT?

DNA Group (TR)'s earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was ₪-0.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ₪-1.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DNA Group (TR)'s annualized ROC % for the quarter that ended in Jun. 2024 was -6.72%. DNA Group (TR)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DNA Group (TR)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -4.11%.

DNA Group (TR) EBIT Historical Data

The historical data trend for DNA Group (TR)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DNA Group (TR) EBIT Chart

DNA Group (TR) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-38.53

-1.59

-2.37

-5.70

-2.17

DNA Group (TR) Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															-3.26	-2.44	-0.98	-1.19	-0.79

Competitive Comparison of DNA Group (TR)'s EBIT

For the Biotechnology subindustry, DNA Group (TR)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DNA Group (TR)'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DNA Group (TR)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DNA Group (TR)'s EV-to-EBIT falls into.

DNA Group (TR) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-1.98 Mil.

DNA Group (TR) (XTAE:DNA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DNA Group (TR)'s annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-1.576 * ( 1 - 1.03% )	/	( (14.022	+	32.391)	/ 2 )
=	-1.5597672	/	23.2065
=	-6.72 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	80.658	-	0.379	-	( 66.698	-	max(0, 0.685	-	66.942	+	66.698	))
=	14.022

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	99.597	-	0.361	-	( 67.333	-	max(0, 0.666	-	67.511	+	67.333	))
=	32.391

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

DNA Group (TR)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.576	/	( ( (0 + max(-0.51099999999999, 0))	+	(0 + max(-0.488, 0)) )	/	2 )
=	-1.576	/	( ( 0	+	0 )	/	2 )
=	-1.576	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.17400000000001)	-	(0.379	+	0	+	0.306)
=	-0.51099999999999

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.178	+	0	+	0)	-	(0.361	+	0	+	0.305)
=	-0.488

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DNA Group (TR)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-1.982	/	48.195
	=	-4.11 %

DNA Group (TR) EBIT Related Terms

Thank you for viewing the detailed overview of DNA Group (TR)'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.